{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:36:27Z","timestamp":1777934187075,"version":"3.51.4"},"reference-count":6,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>Background. Bortezomib is a modified dipeptidyl boronic acid analogue used to treat multiple myeloma, mantle cell lymphoma, and, more recently, renal transplantation graft rejection. As per manufacturer recommendations, bortezomib is to be administered within 8\u2009h of preparation or may be stored for up to 8\u2009h in the vial or a syringe following reconstitution. Preserving unused reconstituted bortezomib beyond these 8\u2009h may allow for cost savings. This study aims to examine the stability of unused reconstituted bortezomib when stored at 4\u00b0C for up to 15 days.<\/jats:p>\n                  <jats:p>Methods. Using an LC-MS\/MS assay, the concentration of reconstituted bortezomib was measured at predetermined time points following storage at 4\u00b0C in the manufacturer vial. Percent bortezomib remaining at a time point was calculated versus initial bortezomib concentration.<\/jats:p>\n                  <jats:p>Results. The concentrations of bortezomib were found to be 51.93\u2009ng\/mL\u2009\u00b1\u20094.60 after 1 day of storage, 57.40\u2009ng\/mL\u2009\u00b1\u20094.77 after 8 days of storage, and 49.43\u2009ng\/mL\u2009\u00b1\u20092.85 after 15 days of storage. The percent of bortezomib remaining was 110.53% and 95.19% after 8 days and 15 days, respectively.<\/jats:p>\n                  <jats:p>Conclusion. Unused reconstituted bortezomib is stable for up to 15 days stored at 4\u00b0C in the original manufacturer vial. Such use of bortezomib may improve cost efficiency by reducing bortezomib waste.<\/jats:p>","DOI":"10.1177\/1078155210386268","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T21:05:17Z","timestamp":1286399117000},"page":"400-402","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Stability of unused reconstituted bortezomib in original manufacturer vials"],"prefix":"10.1177","volume":"17","author":[{"given":"Joshua P","family":"Vanderloo","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia L","family":"Pomplun","sequence":"additional","affiliation":[{"name":"Clinical Oncology, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee C","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA; Center for Drug Policy, University of Wisconsin Hospital and Clinics, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M","family":"Kolesar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA; Analytical Instrumentation Laboratory for Phamacokinetics, Pharmacodynamics and Phamacogenetics, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,10,6]]},"reference":[{"key":"bibr1-1078155210386268","unstructured":"Velcade (bortezomib) package insert\n                      . Cambridge, MA: Millennium Pharmaceuticals, 2009."},{"key":"bibr2-1078155210386268","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318190af83"},{"key":"bibr3-1078155210386268","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181a4b91b"},{"key":"bibr4-1078155210386268","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E620"},{"key":"bibr5-1078155210386268","first-page":"1571","volume":"45","author":"Nichols C","year":"1988","journal-title":"Am J Hosp Pharm"},{"key":"bibr6-1078155210386268","first-page":"1569","volume":"45","author":"Trissel L","year":"1988","journal-title":"Am J Hosp Pharm"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210386268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210386268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:07Z","timestamp":1777688047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155210386268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,6]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1177\/1078155210386268"],"URL":"https:\/\/doi.org\/10.1177\/1078155210386268","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,6]]}}}